Propofol formulated in a lipid vehicle supports the growth of microorganisms. There have been worldwide reports of extrinsic microbial contamination of propofol leading to outbreaks of serious postoperative nosocomial infections. Therefore it is essential that medical professionals follow strict aseptic precautions when handling propofol, as recommended by manufacturers of propofol and the Centers for Disease Control and Prevention. Non-adherence to these recommendations increases the risk of nosocomial postoperative infections, which impose a heavy burden of morbidity and mortality and have serious economic consequences.
Clinical trials with the emulsion formulation of propofol �Diprivan �Diprivan TM , AstraZeneca, Macclesfield, U.K.) �e�an in ��83 with the first commercial �e�an in ��83 with the first commercial with the first commercial the first commercial launches occurrin� in New Zealand and the United Kin�dom in ��86. In Novem�er ��8�, propofol was introduced into the market in the United States of America. It was initially approved for the induction It was initially approved for the induction and maintenance of anaesthesia and its use in �oth inpatient and outpatient sur�ery is now widespread. Propofol has also �ecome a valua�le a�ent for sedation durin� minor procedures for patients in intensive care � . Propofol is water insolu�le and formulated in a lipid vehicle �a soy�ean oil lipid emulsion). As with all intravenous a�ents, propofol must �e handled in an aseptic manner and, since the lipid formulation supports the �rowth of microor�anisms, the manufacturer's prescri�in� information recommends strict aseptic precautions to avoid the possi�ility of accidental extrinsic micro�ial contamination and su�sequent micro�ial �rowth.
Despite these recommendations, within a year of propofol �ein� availa�le in the U.S.A., clusters of postoperative infection were documented, involvin� two or more reports of infection or fever at a sin�le centre, involvin� a sin�le anaesthetist, temporally associated with propofol use and involvin� a sin�le micro�ial contaminant. Cases were also documented in a num�er of countries worldwide; rarely fatalities of �enerally healthy patients were reported. Extensive investi�ation of these cases �oth �y the manufacturer and the Centres for Disease Control and Prevention �CDC) implicated external extrinsic micro�ial contamination of the emulsion due to improper handlin� and use, in contravention of the prescri�in� information. 2 In order to reduce the risk of such �acterial contamination and followin� discussions with the Food and Dru� Administration A�ency �FDA) in USA, the manufacturers incorporated the anti-micro-�ial additive EDTA �disodium edetate) into the propofol formulation. Hart 2 reviewed the selection of EDTA as a suita�le antimicro�ial additive and stated that the essential characteristics were an a�ility to suppress the �rowth of microor�anisms without com-promisin� clinical safety, efficacy or the sta�ility of the emulsion. A num�er of other potential additives were investi�ated includin� �enzyl alcohol, phenylmercuric nitrate, chloro�utanol, chlorocresol, phenol and phenylmercuric acetate, althou�h these were rejected due to potential toxicity issues.
Sodium meta�isulphite was investi�ated more fully �ut this was also rejected due to insufficient micro-�iolo�ical action at Diprivan's TM pH, desta�ilization pH, desta�ilization of the emulsion at a micro�iolo�ically active pH 3 and tri��erin� dimerization of the propofol molecule. The possi�le sensitivity and aller�ic reaction to sulphites has led the USA FDA to impose warnin�s on most pharmaceutical products containin� sulphites, in-cludin� sodium meta�isulphite or sodium sulphite 4 . Sodium sulphite, sodium methyl and propyl hydroxy-�enzoate and sodium calcium edetate were found to �e less a�le to fulfil the essential characteristics of a suita�le antimicro�ial additive. In ���6, the optimal additive that fulfilled the criteria a�reed with the FDA was selected and propofol with 0.005% w/v EDTA was introduced 2, 5 .
As an additional safety measure, the manufacturer introduced the Diprivan TM Pre-Filled Syrin�e �PFS), which is produced under strict aseptic conditions and avoids the risk of contamination of the anaesthetic while drawin� up from a vial into a syrin�e in the clinical situation. The PFS is desi�ned for sin�le use in an individual patient; followin� use, any unused propofol to�ether with infusion equipment is discarded, there�y maintainin� asepsis for the anaesthetic and the infusion equipment.
This review examines reports of extrinsic micro�ial contamination of propofol, postoperative infection followin� propofol use, and the likely causes of infection. Studies desi�ned to investi�ate the a�ility of propofol to support micro�ial �rowth with and without the addition of EDTA to the formulation are reviewed. Data on the frequency of reports of 'clusters' of infection �efore and after the addition of EDTA to the propofol formulation are analysed. Finally, the potential economic and individual patient implications associated with the development and treatment of postoperative nosocomial infections are �riefly considered.
CLINICAL STUDIES OF PROPOFOL CONTAMINATION DURING USE
Several studies have examined contamination of propofol without EDTA durin� clinical use [6] [7] [8] .
We�� et al retrospectively analysed data in a quality assurance data�ase to determine the incidence and clinical si�nificance of administerin� potentially contaminated propofol to patients in the Intensive Care Unit �ICU) 8 . Ei�hteen of three hundred and two syrin�es of propofol without EDTA that had �een used only once were positive for �acterial contamination when samples were cultured. Or�anisms identified included Bacillus spp, Micrococcus kristinae, Gemella spp and Streptococcus salivarius. The incidence of possi�le propofol contamination was 5.�%. The authors concluded that the rate of contamination of propofol syrin�es was low, �ut the study demonstrates that propofol can �ecome contaminated durin� normal clinical use.
Soon� studied the incidence of �acterial contamination of propofol without EDTA durin� usual practice in the operatin� theatres of a sin�le lar�e hospital �roup and investi�ated whether there was any relationship �etween contamination and the practice of multi-dosin� 6 . One hundred samples of propofol were collected from the remnants of syrin�es and ampoules immediately after propofol administration. The samples produced three positive �acterial cultures of Staphylococcus epidermidis, Pseudomonas aeruginosa and a mixed �rowth of or�anisms. The contaminated samples were all from multiple patient doses drawn up from a sin�le ampoule. The authors noted that this technique is most frequently used in paediatric anaesthesia where small doses are required and as such does not comply with the manufacturer's recommendations. The authors warned that the practice of repeated drawin� up of doses from an open ampoule may �e particularly associated with accidental �acterial contamination of propofol. They recommended that propofol should �e handled in an aseptic fashion and drawn up into a syrin�e immediately after openin�. They o�served that propofol infusions contained no preservative or antimicro�ial a�ent 6 . The contamination incidence in this study 6 was 4.�%, in accord with a previous study, which found a 6.3% incidence of �acterial contamination of propofol 7 .
It is clear from these studies that accidental extrinsic micro�ial contamination of propofol or equipment can occur in the operatin� theatre or ICU, even durin� normal clinical use, especially when practice deviates from the manufacturer's recommendations. To minimize the risk of contamination durin� use, all formulations of propofol should �e used for a sin�le patient only, used as soon as possi�le after drawin� up from the vial and handled in an aseptic fashion.
PROPOFOL ASSOCIATED POSTOPERATIvE AND NOSOCOMIAL INFECTIONS
Clusters of postoperative and nosocomial infections linked with propofol use have �een reported �-�� . Henry et al conducted a case-control study in ���� at a community hospital in Ontario, Canada, to determine the risk factors associated with infection � . Five of the patients with infections had �acteraemia and two of these patients died due to infection with Serratia marcescens. All the patients with infections were exposed to the same anaes-thesiolo�ist who administered propofol. The anaes-thesiolo�ist associated with the infections prepared multiple syrin�es of propofol and did not wear �loves when drawin� up or administerin� propofol or when intu�atin� patients. The authors proposed that the hands of the anaesthesiolo�ist had �ecome colonized with Serratia marcescens and that, �ecause he did not wear �loves for fillin� the syrin�es, the propofol syrin�e �ecame contaminated. Without the addition of preservatives, propofol supports rapid micro�ial �rowth at room temperature. The authors su��ested that manufacturers should �e required to develop sin�le-dose vials or to formulate the medication to prevent �acterial �rowth. From a health economics From a health economics a health economics health economics point of view, a US study has estimated that the extra that the extra the extra costs of a sin�le case of �acterial nosocomial infection of �acterial nosocomial infection exceeds US�40,000 s US�40,000 US�40,000 US�40,000 �40,000 �2 . In a cluster of cases of hepatitis C infection fol-lowin� sur�ery investi�ated �y Massari et al �0 , the infection of four patients linked to the administration of propofol and with one potential source patient demonstrates the potential for cross-infection via extrinsically contaminated non-EDTA containin� propofol.
Prior to the introduction of the propofol formulation containin� EDTA, seven unusual out�reaks of postoperative infection involvin� a variety of micro-or�anisms were o�served in the U.S.A. durin� the period June ���0 to Fe�ruary ���3. In an out�reak investi�ated �y McNeil et al �� , �% �4 out of 364) patients developed Candida albicans fun�aemia or endophthalmitis after sur�ery in one hospital, clustered over two days. The anaesthesiolo�ist associated with the infection routinely opened ampoules with un�loved hands and stored filled syrin�es �efore use. The syrin�e in the infusion pump was reused for the duration of the procedure and refilled repeatedly from a second syrin�e. The authors concluded that this unusual cluster of postoperative Candida albicans infections was due to extrinsic micro�ial contamination of the propofol and the likely mechanism for contamination was via the hands of one of the anaes-thesiolo�ists durin� manipulation of propofol. Like other investi�ators, the authors of this study advised that strict aseptic techniques should �e followed when handlin� propofol, in accordance with the manufacturer's recommendations. The authors also noted that the su�sequent addition of preservative to the formulation may have reduced the a�ility of propofol to support micro�ial �rowth. This is supported �y evidence that propofol with EDTA inhi�its the �rowth of Candida albicans 5 .
These studies have demonstrated that clusters of postoperative infection have �een associated with a lack of appropriate asepsis when usin� propofol. In propofol. In propofol. In all the cases descri�ed, there was no antimicro�ial a�ent in the propofol formulation. There is evidence of association �etween infections and deviations from aseptic practice such as un�loved hands, reuse of such as un�loved hands, reuse of such as un�loved hands, reuse of un�loved hands, reuse of hands, reuse of , reuse of reuse of syrin�es, use of vials as multidose vials, and si�nificant delay �etween drawin� up propofol into syrin�es and use.
EFFECT OF EDTA ON BACTERIAL GROWTH IN PROPOFOL IN vITRO
The effect of addition of EDTA on the a�ility of propofol to support micro�ial �rowth has �een inves-ti�ated in vitro �3,�4 . Norie�a et al conducted a prospective study to compare saline with three commercially availa�le preparations of propofol: Propocam Propocam ® �propofol, ABBOTT La�oratories), Recofol ® �propofol, PISA La�oratories), and Diprivan TM �propofol�� propofol�� �� 0.005% EDTA, AstraZeneca) �3 . Ten microor�anisms �Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Candida albicans, Enterococcus faecalis, Serratia marcescens, Acinetobacter calcoaceticus and Enterobacter aerogenes) commonly associated with commonly associated with postoperative infection were chosen for the study and cultured. Followin� incu�ation at room temperature Followin� incu�ation at room temperature ��8-25°C), �acterial �rowth was assessed at 3, 6, �2 and 24 hours. All propofol solutions showed �acterial �rowth compared with the saline control. However for the majority of microor�anisms tested, �rowth was less in the propofol with EDTA formulation. As early as three hours after inoculation, �rowth of Serratia marcescens and Acinetobacter calcoaceticus in propofol with EDTA was lower than in Propocam Propocam ® �P<0.05). Differences were also seen at the later samplin� times.
Fukada et al �4 recently demonstrated that propofol supports the �rowth of a variety of microor�anisms in vitro and this is si�nificantly inhi�ited �y the addition of EDTA �Fi�ure �). Methicillin resistant Methicillin resistant and suscepti�le Staphylococcus aureus �MRSA and MSSA), Pseudomonas aeruginosa and Escherichia coli were cultured at room temperature �22.5°C) in the two anaesthetic formulations and a control solution of saline. The authors noted that in propofol with propofol with EDTA, �rowth of all four strains was suppressed com-, �rowth of all four strains was suppressed compared with the �rowth in propofol without EDTA. For example, after �2 hours: E.coli was reduced 40 fold; MSSA was reduced 8 fold; MRSA and P. aeruginosa were reduced �� fold.
The authors concluded that where propofol is used over several hours, propofol with EDTA offers less risk of �acterial �rowth followin� extrinsic micro�ial contamination and should reduce the incidence of postoperative infections �4 .
These in vitro comparative studies have demonstrated that the addition of an appropriate concentration of EDTA to propofol retards the �rowth of microor�anisms commonly associated with nosocomial infections, even when the cultures are incu-�ated at temperatures commonly found in the ICU and operatin� rooms, for up to 48 hours.
EFFECT OF THE ADDITION OF EDTA ON THE REPORTED INCIDENCE OF NOSOCOMIAL INFECTIONS ASSOCIATED WITH PROPOFOL USE
Estimates of the incidence of nosocomial infections followin� propofol use vary. Bach and Motsch surveyed the literature from ��7� to ���5 usin� the Medline data�ase and evaluated the incidence of infection associated with intravenous anaesthetic a�ents � . They reported that the risk of infection is minimal and often caused �y failure to adhere to aseptic techniques.
An incidence of 0.34% nosocomial infections fol-lowin� anaesthesia was reported �y Hajjar and Girard in France �5 . Infections were si�nificantly more frequent in patients who had received �eneral anaesthesia and in those who were anaesthetized for more than two hours.
An AstraZeneca data�ase holds reports of postoperative infections or fever followin� propofol use. �6 Inspection of the data for USA showed 27� cases in fIgurE �: Growth curve in Diprivan™ and �% propofol injection "Maruishi"™. Reproduced with kind permission of Dr Tomoko Fukada and the editors of Life Support and Anesthesia �LISA) �4 . these cate�ories from Novem�er ��8� to June ���6 �prior to the introduction of propofol with EDTA), , an avera�e of 3� per year. The introduction of the EDTA formulation was phased over two years fol-lowin� June ���6. Durin� the period from June ���6 until Novem�er 2004, there were 74 such case reports, an avera�e of nine per year. This reduction in the incidence of postoperative infection or fever occurred despite a marked increase in the use of propofol �Fi�ure 2). Review of data from the U.K. and France, where the EDTA containin� formulation of propofol has not �een approved, shows a smaller reduction in the incidence of reports of fever and postoperative infection. An avera�e of ei�ht cases per year were reported durin� the period Novem�er ��86 to June ���6, whereas durin� the period July ���6 to Novem�er 2004 there was an avera�e of four cases per year �6 . These data point towards a reduced incidence of postoperative infection or fever followin� the introduction of propofol with EDTA, althou�h propofol with EDTA, althou�h it should �e noted that adverse event reportin� is su�ject to many varia�les and overall there has �een a decreasin� num�er of adverse events reported from these re�ions. .
These findin�s are supported �y a review of propofol with EDTA �y Ovechkin and Ga�arina in Russia �7 . The rate of propofol contamination durin� handlin� is considered to �e 6.3% despite an intensive education campai�n undertaken �y the manufac-turer that focused on dru� handlin� and compliance with aseptic technique. The authors su��est that the actual num�er of cases is likely to �e much hi�her as cases were included only where a definite causal link can �e esta�lished �etween propofol use and contamination. They o�served that, since ���6 in the USA, the EDTA formulation of propofol has �een used in more than thirty million patients, �5% receivin� it for lon�-term sedation. Over this period, there has not �een a sin�le case of infection proven to �e due to extrinsically contaminated Diprivan TM , while such reports continue for areas where the formulation without EDTA is licensed. �5 These data su��est that the incidence of nosocomial infection associated with propofol use is low when recommended procedures are followed. However, an incidence of accidental extrinsic micro�ial contamination of a�out 6% has �een reported and appears predominantly associated with deviations from recommended aseptic protocol durin� use. The avail-a�le data on the incidence of infections and/or fever �efore and after the addition of EDTA to the formulation indicates an a�sence of clusters of infection and a marked reduction in individual occurrences of infection without a clear association with propofol followin� the addition of EDTA.
DISCUSSION
Postoperative nosocomial infection presents a fIgurE 2: Reports of postoperative infections or fever in the U.S.A. and sales of propofol EDTA in the U.S.A. �6 serious medical pro�lem, havin� a si�nificant impact on patient mor�idity and mortality, increasin� health care costs and reducin� hospital mana�ement efficiency. Accidental extrinsic micro�ial contamination of anaesthetic a�ents has �een identified as a risk factor for nosocomial infection. This review has examined factors involved in nosocomial infection followin� propofol use. It is clear that contamination of propofol can occur in the operatin� theatre or ICU, particularly when practice deviates from the manufacturer's recommendations. To minimize the risk of contamination, a two-pron�ed approach has �een shown to �e effective: • The manufacturer's and CDC recommendations and protocols for �ood aseptic practice should �e strictly followed. • Use of an EDTA containin� formulation should �e considered as in vitro comparative studies have demonstrated that the addition of EDTA to propofol retards the �rowth of microor�anisms commonly associated with nosocomial infections, and the availa�le data on the incidence of infections �efore and after the addition of EDTA to a propo-propofol formulation shows �oth an a�sence of clusters formulation shows �oth an a�sence of clusters of infection and su��ests a reduction incidence of individual infections followin� its addition. The in vitro study reported �y Fukada et al �4 indicated that the �rowth of a ran�e of microor�anisms, particularly Pseudomonas aeruginosa, could increase markedly after 24 hours incu�ation in a propofol emulsion, �oth with and without an antimicro�ial additive. This increase in �rowth may �e a reflection of the development of resistance mechanisms such as reduced outer mem�rane permea�ility and the outer mem�rane permea�ility and the over-expression of one or more efflux systems. The manufacturer's prescri�in� information for propofol currently recommends that the emulsion and any syrin�e or infusion line must �e discarded at the end of a procedure or at �2 hours, whichever is the sooner, and �e replaced as appropriate; a precaution a�ainst infections associated with micro�ial �rowth in infusion lines.
The medical economic implications of nosocomial infections have �een noted �y a num�er of authors �8-20 . Re�ollo et al o�served that nosocomial infections si�nificantly prolon� hospital stay and are associated with su�stantial mor�idity, mortality and economic �urden �8 . Kimura refers to a survey in ��76 �y the Study of the Efficacy of Nosocomial Infection Control �SENIC) in the U.S.A., which found that nosocomial infections prolon�ed hospital stay �y an avera�e of 3.6 days per case. Accordin� to data for ���5, nosocomial infection occurred in 5% of patients admitted to hospital and prolon�ed stay �y five to seven days 20 .
In Japan, the extended costs of hospital infections of hospital infections hospital infections infections s associated with post-sur�ical and nosocomial infection in a hospital with a�out �,000 �eds were reviewed �y Kimura 20 . In �astrointestinal tract operations, infections of the sur�ical site prolon�ed hospital stay �y an avera�e of 35.� days per case and they extended 35.� days per case and they extended days per case and they extended and they extended y extended extended costs �y approximately US��2,000 per case, �ased on �y approximately US��2,000 per case, �ased on �2,000 per case, �ased on ,000 per case, �ased on per case, �ased on , �ased on exchan�e rates at the time of pu�lication. Nosocomial . Nosocomial Nosocomial infections attri�uted to MRSA prolon�ed hospital stay �y an avera�e of 66 days per case and extended costs �y approximately US�22,000 per case. The current extended costs of treatment and hospital stay due to nosocomial medical and post-sur�ical site infections are more than US���,000,000 per year. It It It is estimated that improvements in anti-infection that improvements in anti-infection measures in hospitals could prevent 30% of such cases 20 . The use of propofol with EDTA could represent a si�nificant anti-infection measure.
The evidence presented su��ests that the use of a propofol formulation containin� EDTA to�ether with strict adherence to �ood aseptic practice will reduce the risk of nosocomial infections, there�y reducin� the considera�le expense and sufferin� associated with nosocomial infections ori�inatin� from accidental extrinsic contamination of propofol formulations.
